Kura Oncology: Insider Purchases and Pipeline Expansion as a Catalyst for JPMorgan's $30 Price Target
Reading Time: 3 minutes
Kura Oncology (KURA) is making a strategic shift to become a commercial cancer therapeutic provider. JPMorgan sees a revenue potential of around €1,350 million with a price target of $30. Recent insider purchases by the CEO at 9% underline confidence in the pipeline expansion. Precision medicine for specific genetic mutations Kura Oncology's (KURA) business model is based on the development and marketing of precision drugs. The company focuses on the medical needs associated with hard-to-treat blood cancers as well as solid tumors through...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
